UK markets open in 7 hours 19 minutes

Hutchison China MediTech Limited (HCM)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
17.69-2.18 (-10.97%)
At close: 04:00PM EST
17.69 0.00 (0.00%)
After hours: 04:20PM EST
Full screen
Trade prices are not sourced from all markets
Previous close19.87
Open18.85
Bid17.50 x 800
Ask18.00 x 800
Day's range17.58 - 18.89
52-week range7.39 - 28.40
Volume418,879
Avg. volume614,395
Market cap3.06B
Beta (5Y monthly)0.89
PE ratio (TTM)N/A
EPS (TTM)-1.23
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est30.46
  • Globe Newswire

    HUTCHMED Announces License to Takeda to Develop and Commercialize Fruquintinib Outside China

    — HUTCHMED to receive US$400 million upfront on deal closing and up to US$730 million in potential future milestone payments, totaling up to US$1.13 billion, plus royalties on net sales — — Marketing authorization submissions in the U.S., Europe and Japan planned to complete in 2023 — — Partnership approach aligned with HUTCHMED’s path to profitability and strategy to bring its innovative medicines to patients worldwide — — HUTCHMED to host a conference call and webcast at 8:30 a.m. EST (1:30 p.

  • Globe Newswire

    HUTCHMED Announces Agreement with NHSA for Inclusion of ORPATHYS® in the National Reimbursement Drug List in China

    HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Jan. 18, 2023 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX:13) today announces, following negotiations with the China National Healthcare Security Administration (“NHSA”), ORPATHYS® (savolitinib) has been included in the updated National Reimbursement Drug List (“NRDL”) for the treatment of locally advanced or metastatic non-small cell lung cancer (“NSCLC”) adult patients with MET exon 14-skipping alterations who

  • Globe Newswire

    HUTCHMED Completes Patient Enrollment of ESLIM-01, a Phase III Trial of Sovleplenib in Primary Immune Thrombocytopenia in China

    HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Jan. 03, 2023 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM, HKEX:​13) today announces that it has completed patient enrollment of ESLIM-01, a pivotal Phase III clinical trial of sovleplenib for the treatment of adult patients with primary immune thrombocytopenia (“ITP”) in China. The last patient was enrolled on December 31, 2022. The ESLIM-01 study, initiated in October 2021, is a randomized, double blinded, pla